Non-invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA3CT): Design of a Phase IIb, placebo-controlled, double-blind, randomized clinical trial of doxycycline for the reduction of growth of small abdominal aortic aneurysm

Contemporary Clinical Trials

Volumn 48, Issue , 2016, Pages 91-98

  Baxter, B Timothy ^a   Matsumura, Jon ^b   Curci, John ^c   McBride, Ruth ^d   Blackwelder, William C ^e   Liu, Xinggang ^e   Larson, LuAnn ^a   Terrin, Michael L ^e  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d Axio Research   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Abdominal; Aneurysm; Aortic; Clinical trial; Doxycycline

Indexed keywords

BIOLOGICAL MARKER; DOXYCYCLINE; ANTIINFECTIVE AGENT;

ABDOMINAL AORTA ANEURYSM; ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALTERNATIVE HYPOTHESIS; ANALYSIS OF COVARIANCE; ANEURYSM RUPTURE; ARTERY DIAMETER; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INVASIVE PROCEDURE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; ABDOMINAL AORTA; ABDOMINAL AORTIC ANEURYSM; CLINICAL TRIAL; DIAGNOSTIC IMAGING; ORGAN SIZE; PATHOLOGY; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

AGED; ANTI-BACTERIAL AGENTS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; DOUBLE-BLIND METHOD; DOXYCYCLINE; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84963968454     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2016.03.008     Document Type: Article

References (44)

1. Alcorn H.G., Wolfson S.K., Sutton-Tyrrell K., Kuller L.H., O'Leary D. Risk factors for abdominal aortic aneurysms in older adults enrolled in the cardiovascular health study. Arterioscler. Thromb. Vasc. Biol. 1996, 16:963-970.
2. The UK Small Aneurysm Trial Participants Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet 1998, 352:1649-1655.
3. Lederle F.A., Johnson G.R., Wilson S.E., Ballard D.J., Jordan W.D., Blebea J., et al. Rupture rate of large abdominal aortic aneurysms in patients refusing or unfit for elective repair. JAMA 2002, 287:2968-2972.
4. Lederle F.A., Wilson S.E., Johnson G.R., Reinke D.B., Littooy F.N., Acher C.W., et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N. Engl. J. Med. 2002, 346:1437-1444.
5. Schlosser F.J., Tangelder M.J., Verhagen H.J., van der Heijden G.J., Muhs B.E., van der Graaf Y., et al. Growth predictors and prognosis of small abdominal aortic aneurysms. J. Vasc. Surg. 2008, 47:1127-1133.
6. Scott R.A., Wilson N.M., Ashton H.A., Kay D.N. Influence of screening on the incidence of ruptured abdominal aortic aneurysm: 5-year results of a randomized controlled study. Br. J. Surg. 1995, 82:1066-1070.
7. Ashton H.A., Buxton M.J., Day N.E., Kim L.G., Marteau T.M., Scott R.A., et al. The multicentre aneurysm screening study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet 2002, 360:1531-1539.
8. Lindholt J.S., Juul S., Fasting H., Henneberg E.W. Hospital costs and benefits of screening for abdominal aortic aneurysms. Results from a randomised population screening trial. Eur. J. Vasc. Endovasc. Surg. 2002, 23:55-60.
9. United Kingdom EVAR Trial Investigators, Greenhalgh R.M., Brown L.C., Powell J.T., Thompson S.G., Epstein D., Sculpher M.J. Endovascular versus open repair of abdominal aortic aneurysm. N. Engl. J. Med. 2010, 362:1863-1871.
10. De Bruin J.L., Baas A.F., Buth J., Prinssen M., Verhoeven E.L., Cuypers P.W., DREAM Study Group, et al. Long-term outcome of open or endovascular repair of abdominal aortic aneurysm. N. Engl. J. Med. 2010, 362:1881-1889.
11. Lederle F., Freischlag J., Kyriakides T.C., Matsumura J.S., Padberg F., Kohler T.R., et al. OVER veterans affairs cooperative study group. Long-term comparison of endovascular and open repair of abdominal aortic aneurysm. N. Engl. J. Med. 2012, 367(21):1988-1997.
12. Cao P., De Rango P., Verzini F., Parlani G., Romano L., Cieri E., Trial Group C.A.E.S.A.R. Comparison of surveillance versus aortic endografting for small aneurysm repair (CAESAR): results from a randomised trial. Eur. J. Vasc. Endovasc. Surg. 2011, 41:13-25. 10.1016/j.ejvs.2010.08.026.
13. Ouriel K., Clair D.G., Kent K.C., Zarins C.K. Positive impact of endovascular options for treating aneurysms early (PIVOTAL) investigators. Endovascular repair compared with surveillance for patients with small abdominal aortic aneurysms. J. Vasc. Surg. 2010, 51:1081-1087. 10.1016/j.jvs.2009.10.113.
14. Longo G.M., Xiong W., Greiner T.C., Zhao Y., Fiotti N., Baxter B.T. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J. Clin. Invest. 2002, 110:625-632.
15. Dobrin P.B., Mrkvicka R. Failure of elastin or collagen as possible critical connective tissue alterations underlying aneurysmal dilatation. Cardiovasc. Surg. 1994, 2:484-488.
16. Davis V., Persidskaia R., Baca-Regen L., Itoh Y., Nagase H., Persidsky Y., et al. Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1625-1633.
17. Curci J.A., Liao S., Huffman M.D., Shapiro S.D., Thompson R.W. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J. Clin. Invest. 1998, 102:1900-1910.
18. Webster M.W., McAuley C.E., Steed D.L., Miller D.D., Evans C.H. Collagen stability and collagenolytic activity in the normal and aneurysmal human abdominal aorta. Am. J. Surg. 1991, 161:635-638.
19. Carrell T.W., Burnand K.G., Wells G.M., Clements J.M., Smith A. Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation 2002, 105:477-482.
20. Longo G.M., Buda S.J., Fiotta N., Xiong W., Griener T., Shapiro S., et al. MMP-12 has a role in abdominal aortic aneurysms in mice. Surgery 2005, 137:457-462.
21. Cho B.S., Roelofs K.J., Ford J.W., Henke P.K., Upchurch G.R. Decreased collagen and increased matrix metalloproteinase-13 in experimental abdominal aortic aneurysms in males compared with females. Surgery 2010, 147:258-267.
22. McMillan W.D., Tamarina N.A., Cipollone M., Johnson D.A., Parker M.A., Pearce W.H. Size matters: the relationship between MMP-9 expression and aortic diameter. Circulation 1997, 96:2228-2232.
23. Golub L.M., Ramamurthy N.S., McNamara T.F., Greenwald R.A., Rifkin B.R. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit. Rev. Oral Biol. Med. 1991, 2:297-321.
24. Curci J.A., Mao D., Bohner D.G., Allen B.T., Rubin B.G., Reilly J.M., et al. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J. Vasc. Surg. 2000, 31:325-342.
25. Abdul-Hussien H., Hanemaaijer R., Kleemann R., Verhaaren B.F., van Bockel J.H., Lindeman J.H. The pathophysiology of abdominal aortic aneurysm growth: corresponding and discordant inflammatory and proteolytic processes in abdominal aortic and popliteal artery aneurysms. J. Vasc. Surg. 2010, 51:1479-1487.
26. Petrinec D., Liao S., Holmes D.R., Reilly J.M., Parks W.C., Thompson R.W. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J. Vasc. Surg. 1996, 23:336-346.
27. Curci J.A., Petrinec D., Liao S., Golub L.M., Thompson R.W. Pharmacologic suppression of experimental abdominal aortic aneurysms: acomparison of doxycycline and four chemically modified tetracyclines. J. Vasc. Surg. 1998, 28:1082-1093.
28. Prall A.K., Longo G.M., Mayhan W.G., Waltke E.A., Fleckten B., Thompson R.W., et al. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J. Vasc. Surg. 2002, 35:923-929.
29. Mosorin M., Juvonen J., Biancari F., Satta J., Surcel H.M., Leinonen M., et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J. Vasc. Surg. 2001, 34:606-610.
30. Meijer C.A., Stijnen T., Wasser M.N., Hamming J.F., van Bockel J.H., Lindeman J.H. Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Pharmaceutical aneurysm stabilisation trial study group. Ann. Intern. Med. 2013, 159:815-823.
31. Conover W.J. Practical Nonparametric Statistics 1999, Wiley, New York, (396 ff). third ed.
32. McMahon R.P., Harrell F.E. Power calculation for clinical trials when the outcome is a composite ranking of survival and a nonfatal outcome. Control. Clin. Trials 2000, 21:305-312.
33. Haybittle J.L. Repeated assessments of results in clinical trials of cancer treatment. Brit. J. Radiol. 1971, 44(526):793-797. 10.1259/0007-1285-44-526-793.
34. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design, Brit. J. Cancer 1976, 34(6):585-612.
35. Lachin J.M. A review of methods for futility stopping based on conditional power. Stat. Med. 2005, 24(18):2747-2764.
36. Pocock S.J. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977, 64:191-199.
37. Fan Xitao, Felsovalyi Akos, Sivo Stephen A., Keenan Sean C. SAS for Monte Carlo Studies: A Guide for Quantitative Researchers 2002, SAS Institute Inc.
38. Metropolis N., Ulam S. The Monte Carlo method. J. Am. Stat. Assoc. 1949, 44(247):335-341.
39. Center for Disease Control and Prevention National Vital Statistics System. 'Death Rates by 10 year Age Groups: United States and Each State http://www.cdc.gov/nchs/nvss/mortality/gmwk23r.htm.
40. Baxter B.T., Pearce W.H., Waltke E.A., Littooy F.N., Hallett J.W., Kent K.C., et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (phase II) multicenter study. J. Vasc. Surg. 2002, 36:1-12.
41. Frison L., Pocock S.J. Repeating measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat. Med. 1992, 1685-1704.
42. Lederle F.A. Abdominal aortic aneurysm: still no pill. Ann. Intern. Med. 2013, 159:852-853.
43. Kroon A.M., Taanman J.W. Clonal expansion of T cells in abdominal aortic aneurysm: a role for doxycycline as drug of choice?. Int. J. Mol. Sci. 2015, 16(5):11178-11195. 10.3390/ijms160511178.
44. Reeps C., Essler M., Pelisek J., Seidl S., Eckstein H.H., Krause B.J. Increased 18F-fluorodeoxyglucose uptake in abdominal aortic aneurysms in positron emission/computed tomography is associated with inflammation, aortic wall instability, and acute symptoms. J. Vasc. Surg. 2008, 48:417-423.